Buchumschlag

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease$da randomized, open-label, multicenter phase II trial

Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bozorgmehr, Farastuk (Verfasst von) , Christopoulos, Petros (Verfasst von) , Chung, Inn (Verfasst von) , Cvetkovic, Jelena (Verfasst von) , Feißt, Manuel (Verfasst von) , Krisam, Johannes (Verfasst von) , Schneider, Marc (Verfasst von) , Heußel, Claus Peter (Verfasst von) , Kreuter, Michael (Verfasst von) , Müller, Daniel W. (Verfasst von) , Thomas, Michael (Verfasst von) , Rieken, Stefan (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 September 2022
In: BMC cancer
Year: 2022, Jahrgang: 22, Pages: 1-9
ISSN:1471-2407
DOI:10.1186/s12885-022-10074-9
Online-Zugang:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s12885-022-10074-9
Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10074-9
Volltext
Verfasserangaben:Farastuk Bozorgmehr, Petros Christopoulos, Inn Chung, Jelena Cvetkovic, Manuel Feißt, Johannes Krisam, Marc A. Schneider, Claus Peter Heußel, Michael Kreuter, Daniel W. Müller, Michael Thomas and Stefan Rieken
Beschreibung
Zusammenfassung:Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated induction of anti-tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy by the addition of thoracic radiotherapy (TRT).
Beschreibung:Gesehen am 18.10.2022
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-022-10074-9

Ähnliche Einträge